Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jeremy Deutsch (NPI 1528263043)

Field	Value
Entity Type	Individual
Organization	Jeremy Deutsch
Address	818 N Emporia St Ste 403
City	Wichita
State	KS
ZIP	67214
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 15, 2007

Payer Source	Total Paid
Medicare	$5.7M
Medicaid	$0

Key Findings

This provider is effectively single-payer in the dataset: total Medicare revenue is $5.7M and there is no Medicaid billing on file. The absence of any Medicaid claims suggests the provider’s Medicare activity represents the vast majority of public-payer volume available for analysis and limits direct payer-mix comparisons across public programs.

Revenue is highly concentrated in a small set of drug administrations: the precomputed top 3 Medicare codes by revenue account for 53.4% of the provider’s total Medicare revenue. Those top drivers include high-cost oncologic injections (notably J9271, J9145, and J1930), indicating that oncology drug administration is the primary revenue engine for this practice.

The code-level mix indicates a specialty hematology/oncology infusion practice that administers checkpoint inhibitors, monoclonal antibodies, and long-acting injectables. High-revenue codes such as J9271 (pembrolizumab), J9145 (daratumumab), and J9299 (nivolumab) combined with chemotherapy administration code 96413 and infusion-related supportive drugs (e.g., J1627, J0897) point to a care model centered on in-office infusion/biologic therapy rather than primarily procedural or outpatient-surgery services.

For several leading drugs this provider shows unusually large national volumes. J9271 is a notable outlier with 35K claims and $1.5M revenue, ranking #63 of 1841 providers (97th percentile) and described as notably above typical national volume; similarly, J1930 ranks #2 of 56 providers (98th percentile) with $623K revenue and is also described as notably above typical national volume. These ranks position the provider as a major national-volume administrator for specific oncology drugs rather than a typical community prescriber.

Other high-use codes show mixed competitive standing: J9145 (daratumumab) is $731.8K and ranks #6 of 14 providers (62nd percentile), reflecting an unremarkable or typical national volume for that code, while 96413 (chemotherapy administration) is an extreme outlier by rank (#79 of 7514, 99th percentile) indicating the practice delivers chemotherapy at volumes far above typical peers. This pattern suggests the provider combines both exceptionally high drug dispensing for particular agents and unusually high procedural chemotherapy throughput.

Service breadth includes imaging and diagnostic workups consistent with oncology management: PET/CT fusion (78815) appears in the top codes with $260.3K revenue and 243 claims, and PET radiotracer (A9552) also appears, indicating the practice either orders or bills for advanced imaging related to tumor evaluation. Inclusion of comprehensive metabolic panel (80053) and infusion visit E/M codes (99213, 99214, 99205) further supports a full-service outpatient oncology workflow handling new and established patient visits, diagnostics, infusion, and supportive care.

Tenure in Medicare enrollment is long-standing: the NPI was enumerated on 2007-06-15 (~19 years ago), signaling an established presence in the Medicare program. This duration, combined with high rankings on several drug codes, is consistent with a mature practice with sustained infusion and oncology service lines.

Operationally, revenues are skewed toward high-volume, low-paid-per-claim items as well as fewer high-dollar items: examples include very large claim counts with low average paid/claim (e.g., J1439 and J0185 with 25.5K and 25.2K claims respectively but low $/claim), alongside drugs with higher $/claim and substantial revenue (e.g., J9271 at $43 avg paid/claim producing $1.5M). This mix suggests throughput and frequent administration of certain supportive or adjunct therapies in addition to major biologic agents.

For payers analyzing contracting or network strategy, the provider should be considered a significant supplier for certain oncology injectables and chemotherapy administration given multiple top-100 national ranks and two specific codes labeled as notably above typical national volume or extreme outliers. The lack of Medicaid billing means payers focused on Medicaid networks will see little direct volume from this provider in state Medicaid data, while Medicare-focused negotiations should account for concentrated drug-revenue exposure.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

117 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	35,000	$40	$1.5M
J9145	Injection, daratumumab, 10 mg	15,570	$50	$731.8K
J1930	Injection, lanreotide, 1 mg	14,160	$40	$623K
J9299	Injection, nivolumab, 1 mg	24,800	$20	$595.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,020	$40	$273.8K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	240	$1,070	$260.3K
J9173	Injection, durvalumab, 10 mg	3,730	$60	$231.3K
J0897	Injection, denosumab, 1 mg	11,040	$20	$209.8K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	4,050	$30	$137.7K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,790	$60	$107.5K

Showing 1–10 of 117

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 117 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Jeremy Deutsch — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

117 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	5	20	28,900	$40	$1.1M
J9299	7	10	24,550	$20	$637.2K
J1930	1	10	9,180	$40	$402.7K
J9145	2	10	6,660	$50	$394.7K
J9144	4	10	6,300	$40	$257.2K
J9173	3	10	3,480	$60	$230.3K
J1568	4	10	3,690	$30	$129K
Q5115	6	10	2,340	$30	$92.9K
J0897	17	180	2,160	$20	$81.5K
J1627	9	10	15,500	$1	$78.7K

Showing 1–10 of 117

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jeremy Deutsch, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
David Dyer	KS	Ophthalmology Physician	$7.5M	$0
Bassam Mattar	KS	Hematology & Oncology Physician	$7.2M	$0
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Dennis Moore	KS	Hematology & Oncology Physician	$6.7M	$0
Pavan Reddy	KS	Hematology & Oncology Physician	$6.7M	$0
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0
Robert Behrens	IA	Medical Oncology Physician	$5.2M	$0

Nearby Providers

Other providers in the same ZIP code as Jeremy Deutsch, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Craig Resources LLC	KS	Home Health Agency	$0	$97.3M
Paradigm Services Inc	KS	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$42.4M
Wesley Medical Center LLC	KS	General Acute Care Hospital	$0	$30.2M
Gracemed Health Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$18.3M
Healthcore Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$15.3M
Diversified Family Services LLC	KS	Home Health Agency	$0	$13.9M
Alpha Service	KS	Developmentally Disabled Services Day Training Agency	$0	$12.1M
Carepoint Emergency Medicine Kansas LLC	KS	Emergency Medicine Physician	$0	$11.8M
Hunter Health Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$10.4M
Ascension Via Christi Hospitals Wichita Inc.	KS	General Acute Care Hospital	$0	$8.9M

Jeremy Deutsch — Billing Profile & Reimbursement Data

Sign up for Jeremy Deutsch — Billing Profile & Reimbursement Data policy alerts

Jeremy Deutsch — Billing Profile & Reimbursement Data

Sign up for Jeremy Deutsch — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References